Kate Hermans, Ambrx Biopharma interim CEO
Biotech layoffs continue as Ambrx cuts staff and part of its pipeline to extend its cash
It’s been no secret that this year has been rough for biotechs and employees, as companies have been cutting costs and headcounts throughout the year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
